SureTrader
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

$6.6 million 4th Qtr 2017 Tight Estimate

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
tilator Member Profile
 
Followed By 0
Posts 410
Boards Moderated 0
Alias Born 09/14/17
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/16/2018 5:16:42 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/16/2018 5:10:45 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/3/2018 5:13:01 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/29/2018 6:13:48 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/22/2018 6:07:41 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/21/2018 4:38:55 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/21/2018 6:10:39 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/20/2018 5:12:58 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/20/2018 4:37:22 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/20/2018 6:08:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/20/2018 6:08:53 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/19/2018 3:05:46 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/19/2018 6:10:42 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/16/2018 6:14:56 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/16/2018 6:14:55 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/14/2018 9:10:32 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/14/2018 6:08:55 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/1/2018 6:51:35 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/1/2018 6:51:33 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/16/2018 6:32:05 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 11:13:52 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/14/2018 6:54:36 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/9/2018 8:08:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 1/24/2018 8:04:28 AM
Intellipharmaceutics Provides Operational Update GlobeNewswire Inc. - 1/24/2018 8:00:00 AM
tilator   Friday, 11/10/17 05:12:56 PM
Re: AngeloFoca post# 31212
Post # of 34375 
Quote:
$6.6 million 4th Qtr 2017 Tight Estimate



You are right, but the big question is why on earth MNK can sell only 1-2% compared to Accord and Lupin sales even though they got approval together?

This leaves much to gain to MNK.

If MNK got 1000% growth right now, it still would sell only 10% compared to Accord and 20% compared to Lupin.

Well - the numbers are prescription counts, not dollars, but anyway. I suppose you got the point.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist